RAP-219

RAP-219 is Rapport Therapeutics' lead candidate, an oral small molecule that selectively dampens excitatory signaling in the forebrain by blocking a specific subset of AMPA glutamate receptors. The forebrain selectivity is the differentiator: instead of shutting down AMPA receptors brain-wide (the perampanel approach), it only blocks AMPA receptors that carry the TARP γ-8 auxiliary subunit, which is concentrated in the cortex and hippocampus where focal seizures originate [6][11]. After a 30-patient Phase 2a in refractory focal epilepsy completed in 2025 with positive electrographic and clinical seizure-reduction data (77.8% reduction in clinical seizures, p=0.01; 24% seizure freedom) and clean tolerability (10% discontinuation, no psychiatric signal in topline) [3][14], the program moved into two Phase 3 trials now recruiting (FOCUS-1, NCT07563881, n=333; NCT07594119, n=312) [1][2] plus a Phase 2 in bipolar I disorder (NCT07046494) [5]. The commercial pitch is seizure control comparable to Eisai's perampanel (Fycompa, which reached roughly $365M in global sales in 2022 before Eisai divested US rights to Catalyst Pharmaceuticals) [8][15] without the boxed psychiatric warning that has capped Fycompa's uptake. Rough opportunity math: ~600K US adults have inadequately controlled focal epilepsy on adjunctive therapy; at 10% peak share and a cenobamate-like ~$15K WAC, that frames a US peak of ~$900M; at 7% share and $12K WAC, ~$500M. Phase 3 readouts will not arrive before 2027 at the earliest.

First-in-class small molecule, never approved anywhere. Phase 2a in refractory focal epilepsy completed in 2025 (NCT06377930, n=30) [3], with an open-label long-term safety extension recruiting (NCT07219407) [4]. The Phase 3 program launched in late 2025 and early 2026: FOCUS-1 (NCT07563881, n=333) [2] and a parallel Phase 3 (NCT07594119, n=312) [1], both in adults with focal seizures inadequately controlled by existing antiseizure medications. A separate Phase 2 in bipolar I disorder is recruiting (NCT07046494, n=250) [5]. No breakthrough therapy, fast track, or orphan designations for the epilepsy indication have been publicly disclosed as of mid-2026. Rapport (Nasdaq: RAPP) IPO'd in 2024 and has been a single-asset story since; recent 8-K filings track program transitions and financing events [7][9][10]. Cash position as of Q1 2026 is $476.8M with management-guided runway into the second half of 2029, supplemented by a non-dilutive $20M collaboration payment recognized in Q1 from Tenacia Biotechnology (China rights for RAP-219) [14]. That removes financing risk through key readouts, which is unusual for a single-asset small-cap and changes the risk picture materially. Phase 3 readouts are likely 2027 to 2028 given enrollment timelines; the long-term safety study extends well beyond that. The bipolar Phase 2 readout, guided to Q4 2026, is the next near-term de-risking event and the first test of whether the forebrain-selective AMPA hypothesis generalizes beyond seizures [14].

Brain cells talk to each other using glutamate, the main 'go' signal. AMPA receptors are the receivers on the listening neuron, and when too many fire too fast, you get a seizure. Eisai's perampanel (Fycompa) blocks AMPA receptors everywhere in the brain. It works, but the side effects (sedation, dizziness, and a black box warning for psychiatric and behavioral reactions including aggression) limit how high you can dose it [8]. RAP-219 takes a more targeted swing. AMPA receptors do not sit alone on the neuron surface; they are partnered with auxiliary proteins called TARPs that modulate how they fire [11]. TARP γ-8 (encoded by CACNG8) concentrates in the forebrain, specifically the hippocampus and cortex, where most focal seizures originate [11][6]. By only blocking AMPA receptors that carry TARP γ-8, RAP-219 should quiet the seizure-prone forebrain while leaving cerebellar AMPA receptors (which handle motor coordination) untouched. Genetic and pharmacological work in rodents supports the thesis: TARP γ-8-selective negative allosteric modulators reduce seizures without the ataxia and sedation that plague broad AMPA blockers [6]. Rapport is not the only group to have chased this mechanism. Janssen ran a TARP γ-8 NAM tool compound, JNJ-55511118, through preclinical and pharmacology characterization but never advanced a TARP γ-8 NAM into late-stage clinical trials [16]. RAP-219 is, as of mid-2026, the most clinically advanced asset on this mechanism. Whether the selectivity translates to humans, and whether it is enough to dodge perampanel's psychiatric signal, is the bet the Phase 3 program is testing.

Two Phase 3 trials anchor the program. FOCUS-1 (NCT07563881) is a 333-patient randomized study in adults with focal-onset seizures inadequately controlled by current antiseizure medications; the primary endpoint is median percent change in seizure frequency over the maintenance period [2]. A parallel Phase 3 (NCT07594119) enrolls 312 patients on similar design [1]. Both are adjunctive (added on top of a patient's existing seizure medications) with placebo control. That is the standard regulatory path for focal epilepsy antiseizure medications, mirroring the studies that supported perampanel, cenobamate, and brivaracetam. Median percent reduction in seizure frequency and responder rate (proportion achieving ≥50% reduction) are the conventional primary and key secondary endpoints; FDA has accepted this design for every modern focal epilepsy approval [8]. Rapport has not publicly disclosed an end-of-Phase 2 FDA agreement document, so it is not confirmed whether two positive Phase 3 trials will suffice for NDA submission versus the more common single-key-plus-supportive scheme; investors should ask on the next earnings call. The completed Phase 2a (NCT06377930) was small (n=30) and ran in refractory focal epilepsy patients with implanted seizure-counting devices that captured 'long episodes' of electrographic activity, an objective biomarker that bypasses patient-reported seizure diary error [3]. Topline: the trial hit its primary endpoint with a statistically significant reduction in long episodes versus baseline over 8 weeks, plus a 77.8% reduction in clinical seizures (p=0.01) and 24% seizure-freedom rate (p<0.0001); follow-up data presented at AAN 2026 showed sustained reductions [3][14]. Tolerability: 10% discontinuation, most treatment-emergent adverse events mild, three serious adverse events none assessed as drug-related, no psychiatric signal flagged in topline [14]. The long-term safety extension (NCT07219407) will accumulate exposure data needed for the eventual NDA package [4].

Our model estimates a 28% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 51%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design; it is held back by the sponsor's thin or weak approval record, smaller-than-typical enrollment for this phase, and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the largest. The Phase 2a was 30 patients with electrographic endpoints; whether that signal scales to a 333-patient diary-based Phase 3 is open. AMPA-class drugs have historically shown smaller separation from placebo as trials enlarge. Safety risk: even with forebrain selectivity, RAP-219 still acts on AMPA receptors in the very brain regions that mediate mood, cognition, and behavior. Perampanel's boxed warning came from psychiatric and behavioral adverse events (aggression, hostility, suicidality), and FDA will scrutinize RAP-219 for the same signals [8]. The Phase 2a topline did not flag a psychiatric signal in the 30-patient sample [14], but the sample is too small and the exposure too short to rule one out at Phase 3 scale. Selectivity reduces but does not eliminate that mechanistic risk. Execution risk is lower than typical for single-asset small biotech: Rapport ended Q1 2026 with $476.8M and guides runway into H2 2029, past expected Phase 3 readouts, so dilution risk before key data is muted [14]. Commercial risk is the more underrated tail. Focal epilepsy adjunctive market is crowded. Cenobamate (SK Biopharmaceuticals' Xcopri) is winning share with the best seizure-freedom rates in class [13]; brivaracetam and lacosamide are entrenched; perampanel is generic in most major markets. To take share, RAP-219 has to show clear advantage on either efficacy or tolerability versus modern standard of care, not just versus placebo. Payers will demand head-to-head context that Phase 3 will not provide.

Worth watching. The mechanism is biologically smart and addresses a real unmet need in focal epilepsy tolerability. Rapport's Phase 2a used objective electrographic seizure capture rather than patient diaries, which is a more reliable Phase 2 signal than most antiseizure programs produce [3][14]. Clean tolerability in Phase 2a is a meaningful early credentialing event for the forebrain-selectivity thesis, though 30 patients is too small to call the psychiatric risk resolved. The cash position (runway into H2 2029) removes the most acute single-asset small-cap risk and means the next inflection events are pure clinical, not financing-dependent. The Phase 3 trials only started recruiting in late 2025 and early 2026, so meaningful focal epilepsy readouts are at least two years away [1][2]. The signal to watch in the meantime: enrollment pace on FOCUS-1, any psychiatric or behavioral signal from the long-term safety extension (NCT07219407) at extended exposure, and the Phase 2 bipolar I readout (NCT07046494, guided Q4 2026) as a separate tolerability and mechanism credentialing event [4][5][14]. The bipolar trial is the wild card. Positive data there would suggest the forebrain-selective AMPA modulation hypothesis generalizes beyond seizures and would substantially de-risk the broader platform thesis for Rapport. Check back at the Q4 2026 bipolar readout and watch 8-K filings from Rapport for safety updates from the long-term extension.